US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

 
• By Derrick Gingery
  
increasing costs
The FDA's cost to review NME NDAs and BLAs in FY 2023 was the second-highest total since FY 2009. • Source: Shutterstock

More from User Fees

More from Pathways & Standards